Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy

Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy

Background: To characterize humoral response after standard anti-SARS-CoV-2 vaccination in Rituximab-treated patients and to determine the optimal time point after last Rituximab treatment for appropriate immunization. Methods: Sixty-four patients who received Rituximab within the last seven years p...

Full description

Bibliographic Details
Main Authors: Maximilian Töllner, Claudius Speer, Louise Benning, Marie Bartenschlager, Christian Nusshag, Christian Morath, Martin Zeier, Caner Süsal, Paul Schnitzler, Wilhelm Schmitt, Raoul Bergner, Ralf Bartenschlager, Hanns-Martin Lorenz, Matthias Schaier
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Journal of Clinical Medicine
Subjects:
COVID-19
Rituximab
vaccination
Online Access:https://www.mdpi.com/2077-0383/11/6/1739

Internet

https://www.mdpi.com/2077-0383/11/6/1739

Similar Items